Autoantibodies to islet antigen-2 are associated with HLA-DRB1*07 and DRB1*09 haplotypes as well as DRB1*04 at onset of type 1 diabetes: the possible role of HLA-DQA in autoimmunity to IA-2
To further our understanding of antigen presentation by HLA class II molecules, we have examined the influence of HLA class II genotype on expression of autoantibodies to islet antigen-2 (IA-2A).
HLA class II genotype and IA-2A were determined within 3 months of diagnosis in 618 patients with type 1 diabetes (median age 11 years [range 0.7–20.9]). Antibodies to the juxtamembrane region of IA-2 were measured by a radiobinding assay in 481 of 484 IA-2A-positive patients.
IA-2A prevalence was highest in patients carrying at least one HLA-DRB1*04-DQA1*0301 (385 of 450; 86%), DRB1*07-DQA1*(0201 or 0301) (58 of 64; 91%) or DRB1*09-DQA1*0301 haplotype (18 of 19; 95%). Multiple regression showed that IA-2A were strongly associated with the number of these haplotypes carried; only 69 of 132 (52%) patients carrying none of these haplotypes had IA-2A, compared with 322 of 391 (82%) patients with one and 93 of 95 (98%) with two of these haplotypes (p < 0.001). IA-2 juxtamembrane antibodies were less frequent in IA-2A-positive patients with one (35%) or two (36%) DRB1*03-DQB1*02 or DRB1*07-DQB1*02 haplotypes than in those negative for these haplotypes (52%) (p = 0.002), but showed an independent positive association with IA-2A level (p < 0.001).
HLA class II alleles strongly influence the prevalence of IA-2A. The high IA-2A prevalence in patients carrying DRB1*04, DRB1*07 and DRB1*09 alleles in linkage disequilibrium with DQA1*0301 or the closely related DQA1*0201 suggests the humoral response to IA-2 may be driven by HLA-DQA1 genes.
- Genovese, S, Bonfanti, R, Bazzigaluppi, E (1996) Association of IA-2 autoantibodies with HLA DR4 phenotypes in IDDM. Diabetologia 39: pp. 1223-1226 CrossRef
- Bingley, PJ, Bonifacio, E, Williams, AJ, Genovese, S, Bottazzo, GF, Gale, EA (1997) Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes 46: pp. 1701-1710 CrossRef
- Naserke, HE, Ziegler, AG, Lampasona, V, Bonifacio, E (1998) Early development and spreading of autoantibodies to epitopes of IA-2 and their association with progression to type 1 diabetes. J Immunol 161: pp. 6963-6969
- Bingley, PJ, Bonifacio, E, Mueller, PW (2003) Diabetes Antibody Standardization Program: first assay proficiency evaluation. Diabetes 52: pp. 1128-1136 CrossRef
- Lambert, AP, Gillespie, KM, Thomson, G (2004) Absolute risk of childhood-onset type 1 diabetes defined by human leukocyte antigen class II genotype: a population-based study in the United Kingdom. J Clin Endocrinol Metab 89: pp. 4037-4043 CrossRef
- Andersson, G (1998) Evolution of the HLA DR region. Front Biosci 27: pp. d739-d745
- Huck, C, Endl, J, Walk, T (2001) HLA-DR53 molecules restrict glutamic acid decarboxylase peptide presentation to T cells of a Type I diabetes patient: specification of the trimolecular HLA-peptide/T cell receptor complex. Diabetologia 44: pp. 70-80 CrossRef
- Lee, KH, Wucherpfennig, KW, Wiley, DC (2001) Structure of a human insulin peptide-HLA-DQ8 complex and susceptibility to type 1 diabetes. Nat Immunol 2: pp. 501-507 CrossRef
- Kawasaki, E, Sera, Y, Fujita, N (2001) Association between IA-2 autoantibody epitope specificities and age of onset in Japanese patients with autoimmune diabetes. J Autoimmun 17: pp. 323-331 CrossRef
- Redondo, MJ, Babu, S, Zeidler, A (2006) Specific human leukocyte antigen DQ influence on expression of antiislet autoantibodies and progression to type 1 diabetes. J Clin Endocrinol Metab 91: pp. 1705-1713 CrossRef
- Autoantibodies to islet antigen-2 are associated with HLA-DRB1*07 and DRB1*09 haplotypes as well as DRB1*04 at onset of type 1 diabetes: the possible role of HLA-DQA in autoimmunity to IA-2
Volume 51, Issue 8 , pp 1444-1448
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- HLA class II
- IA-2 autoantibodies
- Juxtamembrane antibodies
- Type 1 diabetes
- Industry Sectors
- Author Affiliations
- 1. Diabetes and Metabolism, Clinical Science at North Bristol, University of Bristol Medical School Unit, Southmead Hospital, Bristol, BS10 5NB, UK
- 2. Department of Clinical Chemistry, San Raffaele Scientific Institute, Milan, Italy